No abstract available.
Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Arthritis, Psoriatic* ; Adalimumab ; Infliximab

No abstract available.
Adalimumab ; Antibodies, Monoclonal, Humanized

No abstract available.
Adalimumab ; Antibodies, Monoclonal, Humanized

Since the late 1990s, based on scientific advancement and biotechnological improvement, many effective drugs such as leflunomide and biologic agents for rheumatoid arthritis (RA) have been developed. These include TNF-alpha inhibitors such as etanercept, infliximab, and adalimumab, a peripheral B-cell depleting agent such as rituximab, CTLA-4 Ig such as abatacept, and IL-1 receptor antagonist such as anakira. These new agents have provided good efficacy in the treatment of patents with severe or refractory rheumatoid arthritis and have provided retardation or prevention of radiographic progression or joint destruction despite some side effects such as tuberculosis, infection, malignancies. In this review, new therapeutic alternatives would be given, and chances for more improved outcomes in the care of patients with rheumatoid arthritis provided.
Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal, Murine-Derived ; Arthritis, Rheumatoid ; B-Lymphocytes ; Humans ; Immunoconjugates ; Immunoglobulin G ; Interleukin-1 ; Isoxazoles ; Joints ; Receptors, Tumor Necrosis Factor ; Tuberculosis ; Tumor Necrosis Factor-alpha ; Rituximab ; Abatacept ; Adalimumab ; Infliximab ; Etanercept

Targeted agents increase response rates and improved overall survival in treatment of metastatic gastrointestinal cancer. Therefore, physicians pay more attention to the role of targeted agents in treatment of local advanced gastrointestinal cancer. The clinical trials are ongoing to evaluate the efficacy of Trastuzumab in neoadjuvant treatment of local advanced gastric cancer with HER-2 gene over expression. Many studies reported Cetuximab plus chemotherapy as a conversion treatment improve R0 resection rates and prolonged overall survival of the patients with potentially resectable colorectal cancer liver metastasis with wild type KRAS gene status. A phase III( clinical trial is assessing the conversion efficacy of Bevacizumab in unresectable disease with KRAS gene mutation. Current evidence showed that neoadjuvant therapy of targeted agents did not prolong survival of patients with resectable liver metastasis. However, this is controversial. In neoadjuvant therapy of local advanced rectal cancer, Cetuximab did not improve the rates of pathological complete response in most of the phase II( trials. Furthermore, there are no phase III( trials to assess the role of Bevacizumab. Compared to chemotherapy alone for metastatic cancer, it is more important to evaluate the interaction and synergistic action of targeted agents, cytotoxic drugs, surgery and radiation, to make a scientific multidisciplinary model in comprehensive treatment of local advanced cancer.
Antibodies, Monoclonal, Humanized ; Antineoplastic Agents ; Bevacizumab ; Cetuximab ; Gastrointestinal Neoplasms ; drug therapy ; Humans ; Liver Neoplasms ; Molecular Targeted Therapy ; Neoadjuvant Therapy ; Trastuzumab

Although the success of trastuzumab and rituximab for treatment of breast cancer and non-Hodgkins lymphoma, respectively, suggests that monoclonal antibodies (mAbs) will become important therapeutic agents against a wider range of cancers, useful therapeutic Abs are not yet available for the majority of the human cancers because of our lack of knowledge of which antigens (Ags) are likely to become useful targets. We established a procedure for comprehensive identification of such Ags through the extensive isolation of human mAbs that may be therapeutic. Using the phage-display Ab library we isolated a large number of human mAbs that bind to the surface of tumor cells. They were individually screened by immunostaining, and clones that preferentially and strongly stained the malignant cells were chosen. The Ags recognized by those clones were isolated by immunoprecipitation and identified by mass spectrometry (MS). We isolated 2,114 mAbs with unique sequences and identified 25 distinct Ags highly expressed on several carcinomas. Of those 2,114 mAbs 434 bound to specifically to one of the 25 Ags. I am going to discuss how we could select proper target Ags for therapeutic Abs and candidate clones as therapeutic agents.
Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal, Murine-Derived ; Breast Neoplasms ; Clone Cells ; Humans ; Immunoprecipitation ; Lymphoma, Non-Hodgkin ; Mass Spectrometry ; Rituximab ; Trastuzumab

Although the success of trastuzumab and rituximab for treatment of breast cancer and non-Hodgkins lymphoma, respectively, suggests that monoclonal antibodies (mAbs) will become important therapeutic agents against a wider range of cancers, useful therapeutic Abs are not yet available for the majority of the human cancers because of our lack of knowledge of which antigens (Ags) are likely to become useful targets. We established a procedure for comprehensive identification of such Ags through the extensive isolation of human mAbs that may be therapeutic. Using the phage-display Ab library we isolated a large number of human mAbs that bind to the surface of tumor cells. They were individually screened by immunostaining, and clones that preferentially and strongly stained the malignant cells were chosen. The Ags recognized by those clones were isolated by immunoprecipitation and identified by mass spectrometry (MS). We isolated 2,114 mAbs with unique sequences and identified 25 distinct Ags highly expressed on several carcinomas. Of those 2,114 mAbs 434 bound to specifically to one of the 25 Ags. I am going to discuss how we could select proper target Ags for therapeutic Abs and candidate clones as therapeutic agents.
Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal, Murine-Derived ; Breast Neoplasms ; Clone Cells ; Humans ; Immunoprecipitation ; Lymphoma, Non-Hodgkin ; Mass Spectrometry ; Rituximab ; Trastuzumab

The efficacy of anti-TNF-alpha antibodies including infliximab and adalimumab for refractory intestinal Behcet's disease has recently been demonstrated in a series of case reports. The efficacy of switching to a different kind of anti-TNF-alpha agent in the face of refractoriness to one kind of anti-TNF-alpha agent, a common practice of proven efficacy in rheumatoid arthritis, has yet not been reported for intestinal Behcet's disease. In the present study, we report a case of 52-year-old female patient with intestinal Behcet's disease, who lost initial good response to infliximab, and was refractory to subsequent administrations of adalimumab. Her recent relapse of intestinal lesions could be successfully treated with etanercept. This case suggests that switching to etanercept might be a reasonable therapeutic option in case of intestinal Behcet's disease with secondary non-response to anti-TNF-alpha antibodies that is most likely to be mediated by anti-drug antibody.
Antibodies ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Arthritis, Rheumatoid ; Female ; Humans ; Immunoglobulin G ; Receptors, Tumor Necrosis Factor ; Recurrence ; Adalimumab ; Infliximab ; Etanercept

Rituximab has been shown to be effective in rheumatoid arthritis (RA) and is recommended for patients exhibiting an inadequate response to tumor necrosis factor (TNF) inhibitors. To date, there have been no reports of tuberculosis in RA patients treated with rituximab. We report the use of rituximab in a TNF inhibitor-refractory RA patient who had developed tuberculosis. A 52-year-old man with RA had been treated with adalimumab for 3 months, but failed to respond well to the treatment. He reported fever, coughing, sputum, and weight loss. He was diagnosed with pulmonary tuberculosis and started anti-tuberculosis medication. His arthritis was not controlled for despite increasing the dose of prednisolone. He was treated with rituximab without serious adverse effects. Sixteen weeks later, he demonstrated improvement with both arthritis and tuberculosis.
Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal, Murine-Derived ; Arthritis ; Arthritis, Rheumatoid ; Cough ; Fever ; Humans ; Middle Aged ; Prednisolone ; Sputum ; Tuberculosis ; Tuberculosis, Pulmonary ; Tumor Necrosis Factor-alpha ; Weight Loss ; Adalimumab ; Rituximab

Rituximab has been shown to be effective in rheumatoid arthritis (RA) and is recommended for patients exhibiting an inadequate response to tumor necrosis factor (TNF) inhibitors. To date, there have been no reports of tuberculosis in RA patients treated with rituximab. We report the use of rituximab in a TNF inhibitor-refractory RA patient who had developed tuberculosis. A 52-year-old man with RA had been treated with adalimumab for 3 months, but failed to respond well to the treatment. He reported fever, coughing, sputum, and weight loss. He was diagnosed with pulmonary tuberculosis and started anti-tuberculosis medication. His arthritis was not controlled for despite increasing the dose of prednisolone. He was treated with rituximab without serious adverse effects. Sixteen weeks later, he demonstrated improvement with both arthritis and tuberculosis.
Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal, Murine-Derived ; Arthritis ; Arthritis, Rheumatoid ; Cough ; Fever ; Humans ; Middle Aged ; Prednisolone ; Sputum ; Tuberculosis ; Tuberculosis, Pulmonary ; Tumor Necrosis Factor-alpha ; Weight Loss ; Adalimumab ; Rituximab